Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Replicative Cell Senescence02:15

Replicative Cell Senescence

3.7K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.7K
Cancer Prevention02:59

Cancer Prevention

6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.2K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted cancer therapy: the initial high concentration may slow down the selection for resistance.

Aging·2024
Same author

From osimertinib to preemptive combinations.

Oncotarget·2024
Same author

My battle with cancer. Part 1.

Oncoscience·2024
Same author

Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?

Aging·2023
Same author

Evaluation of off-label rapamycin use to promote healthspan in 333 adults.

GeroScience·2023
Same author

Apoptotic cell death in disease-Current understanding of the NCCD 2023.

Cell death and differentiation·2023
Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026
Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026
Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026
Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026
Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026
Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026
See all related articles

Related Experiment Video

Updated: Aug 2, 2025

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

431

Cancer prevention with rapamycin.

Mikhail V Blagosklonny1

  • 1Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Oncotarget
|April 14, 2023
PubMed
Summary
This summary is machine-generated.

Rapamycin (sirolimus) and its analogs are anti-cancer drugs that delay cancer by targeting pre-cancerous cells and slowing aging. Clinical trials are needed to confirm cancer prevention in high-risk individuals.

Keywords:
agingcancerchemopreventionlungrapamycin

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.5K

Related Experiment Videos

Last Updated: Aug 2, 2025

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

431
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.5K

Area of Science:

  • Oncology
  • Gerontology
  • Pharmacology

Background:

  • Cancer is a complex disease often associated with aging.
  • Rapamycin (sirolimus) and rapalogs (everolimus) exhibit anti-cancer and anti-aging properties.
  • These drugs target cellular pathways involved in proliferation and aging.

Purpose of the Study:

  • To evaluate the cancer-preventive potential of rapamycin and its analogs.
  • To explore the mechanisms by which rapamycin may delay cancer onset.
  • To assess the relevance of preclinical findings to human cancer prevention.

Main Methods:

  • Review of preclinical data from numerous murine cancer models.
  • Analysis of clinical data from organ-transplant patients treated with rapamycin or everolimus.
  • Consideration of rapamycin's effects on cell proliferation and aging.

Main Results:

  • Rapamycin demonstrated robust and reproducible cancer prevention in diverse murine models.
  • The drug effectively slowed tumor progression and delayed cancer onset in various settings.
  • Clinical data in transplant patients suggest cancer-preventive effects.
  • Rapamycin's mechanism involves targeting pre-cancerous cells and slowing organismal aging.

Conclusions:

  • Rapamycin and its analogs show significant promise as cancer-preventive agents.
  • The dual action of targeting pre-cancerous cells and slowing aging contributes to cancer delay.
  • Further clinical investigation in high-risk populations, such as smokers, is warranted.